S&P 500   3,327.77 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   3,327.77 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   3,327.77 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   3,327.77 (+0.64%)
DOW   27,201.52 (+1.39%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
Log in

NASDAQ:BLUEbluebird bio Stock Price, Forecast & News

$62.06
-0.38 (-0.61 %)
(As of 08/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$61.90
Now: $62.06
$63.80
50-Day Range
$59.50
MA: $63.28
$67.55
52-Week Range
$38.95
Now: $62.06
$126.39
Volume473,917 shs
Average Volume1.17 million shs
Market Capitalization$3.45 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.32
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; and TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Read More
bluebird bio logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLUE
CUSIPN/A
Phone339-499-9300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$44.67 million
Book Value$23.22 per share

Profitability

Net Income$-789,610,000.00
Net Margins-1,531.04%

Miscellaneous

Employees1,090
Market Cap$3.45 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable
$62.06
-0.38 (-0.61 %)
(As of 08/5/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

How has bluebird bio's stock been impacted by COVID-19 (Coronavirus)?

bluebird bio's stock was trading at $61.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BLUE stock has increased by 0.9% and is now trading at $62.06.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of bluebird bio?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for bluebird bio
.

When is bluebird bio's next earnings date?

bluebird bio is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for bluebird bio
.

How were bluebird bio's earnings last quarter?

bluebird bio Inc (NASDAQ:BLUE) announced its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($3.64) earnings per share for the quarter, beating analysts' consensus estimates of ($4.05) by $0.41. The biotechnology company had revenue of $21.90 million for the quarter, compared to analysts' expectations of $8 million. bluebird bio had a negative return on equity of 60.05% and a negative net margin of 1,531.04%. The business's revenue was up 75.2% compared to the same quarter last year. During the same period last year, the firm earned ($2.99) earnings per share.
View bluebird bio's earnings history
.

What price target have analysts set for BLUE?

18 analysts have issued 1 year price targets for bluebird bio's stock. Their forecasts range from $70.00 to $160.00. On average, they anticipate bluebird bio's stock price to reach $107.77 in the next year. This suggests a possible upside of 73.7% from the stock's current price.
View analysts' price targets for bluebird bio
.

Has bluebird bio been receiving favorable news coverage?

Press coverage about BLUE stock has been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. bluebird bio earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future.
View the latest news about bluebird bio
.

Who are some of bluebird bio's key competitors?

What other stocks do shareholders of bluebird bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include Opko Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Celgene (CELG), Incyte (INCY), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU) and Medivation (MDVN).

Who are bluebird bio's key executives?

bluebird bio's management team includes the following people:
  • Mr. Nick Leschly, Pres, CEO & Director (Age 46)
  • Mr. Jason F. Cole, Chief Operating & Legal Officer and Sec. (Age 46)
  • Dr. Philip D. Gregory, Chief Scientific Officer (Age 48)
  • Mr. Jeffrey T. Walsh, Chief Strategy Officer (Age 53)
  • Dr. David M. Davidson, Chief Medical Officer (Age 55)

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

Who are bluebird bio's major shareholders?

bluebird bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (2.10%), Frontier Capital Management Co. LLC (0.81%), Candriam Luxembourg S.C.A. (0.75%), Russell Investments Group Ltd. (0.26%), Swiss National Bank (0.26%) and Rhenman & Partners Asset Management AB (0.19%). Company insiders that own bluebird bio stock include Alison Cecily Finger, David Davidson, James Mandell, Jason Cole, Jeffrey T Walsh, Joanne Smith-Farrell, Kory James Wentworth, Nick Leschly, Philip D Gregory, Susanna Gatti High and William D Baird III.
View institutional ownership trends for bluebird bio
.

Which major investors are selling bluebird bio stock?

BLUE stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, SG Americas Securities LLC, Rothschild Investment Corp IL, and Brinker Capital Inc.. Company insiders that have sold bluebird bio company stock in the last year include Alison Cecily Finger, David Davidson, Jeffrey T Walsh, Joanne Smith-Farrell, Kory James Wentworth, Nick Leschly, Philip D Gregory, and William D Baird III.
View insider buying and selling activity for bluebird bio
.

Which major investors are buying bluebird bio stock?

BLUE stock was purchased by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Frontier Capital Management Co. LLC, Candriam Luxembourg S.C.A., Russell Investments Group Ltd., Rhenman & Partners Asset Management AB, Swiss National Bank, FCG Advisors LLC, and AE Wealth Management LLC.
View insider buying and selling activity for bluebird bio
.

How do I buy shares of bluebird bio?

Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is bluebird bio's stock price today?

One share of BLUE stock can currently be purchased for approximately $62.06.

How big of a company is bluebird bio?

bluebird bio has a market capitalization of $3.45 billion and generates $44.67 million in revenue each year. The biotechnology company earns $-789,610,000.00 in net income (profit) each year or ($14.31) on an earnings per share basis. bluebird bio employs 1,090 workers across the globe.

What is bluebird bio's official website?

The official website for bluebird bio is www.bluebirdbio.com.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.